ESSA Pharma Seeks Court Approval for Cash Distribution Amid XenoTherapeutics Merger
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ESSA Pharma ( (EPIX) ) has issued an announcement.
ESSA Pharma Inc. announced its intention to apply to the Supreme Court of British Columbia for an interim order to hold a special meeting for approving its business combination with XenoTherapeutics, Inc., and for a cash distribution to shareholders before the transaction’s closure. This move aims to expedite cash distribution to shareholders, with an estimated payout of approximately US$1.91 per common share, marking a significant step in the company’s strategic transaction with XenoTherapeutics.
The most recent analyst rating on (EPIX) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on ESSA Pharma stock, see the EPIX Stock Forecast page.
Spark’s Take on EPIX Stock
According to Spark, TipRanks’ AI Analyst, EPIX is a Neutral.
ESSA Pharma’s overall score reflects significant financial challenges with no revenue and ongoing losses. Technical indicators provide some positive signals, but caution is advised due to potential overbought conditions. The negative P/E ratio and lack of dividends further underline investment risks.
To see Spark’s full report on EPIX stock, click here.
More about ESSA Pharma
ESSA Pharma Inc. is a pharmaceutical company that was previously focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer.
Average Trading Volume: 237,960
Technical Sentiment Signal: Sell
Current Market Cap: $82.56M
For an in-depth examination of EPIX stock, go to TipRanks’ Overview page.
